High-dose escitalopram for the treatment of obsessive-compulsive disorder

International Clinical Psychopharmacology

Volumn 23, Issue 1, 2008, Pages 49-53

  Rabinowitz, Ilan ^a   Baruch, Yehuda ^b   Barak, Yoram ^b  

^a YOTAM Treatment Center   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

Author keywords

Escitalopram; High dose; Obsessive compulsive disorder; Refractory; Selective serotonin reuptake inhibitors; Treatment resistance

Indexed keywords

ESCITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOM; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 37349026204     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282f0f0c5     Document Type: Article

References (28)

1. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M (2005). Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387-400.
2. American Psychiatric Association (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, Virginia: American Psychiatric Association.
3. Ashton AK, Mahmood A, Iqbal F (2005). Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram. J SexMarital Ther 31:257-262.
4. El Mansari M, Blier P (2006). Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:362-373.
5. Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107-129.
6. Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17:430-439.
7. Galvão-de Almeida A, Quarantini LC, Góis CR, Santos-Jesus R, Miranda-Scippa ÂMA, de Oliveira IR, et al. (2007). Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectr 12:519-524.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
9. Guy W (1976). ECDEU assessment manual for psychopharmacology. Biometric Laboratory. The George Washington University, Kensington, Maryland. US Dept. of Health, Education, and Welfare - DHEW Publication No. (ADM) 218-222.
10. Heyman I, Mataix-Cols D, Fineberg NA (2006). Obsessive-compulsive disorder. BMJ 333:424-429.
11. Hollander E, Allen A, Steiner M,Wheadon DE, Oakes R, Burnham DB, Paroxetine OCD Study Group (2003). Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64:1113-1121.
12. Husted DS, Shapira NA (2004). A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation. CNS Spectr 9:833-847.
13. Lopez AD, Murray CCJL (1998). The global burden of disease, 1990-2020. Nat Med 4:1241-1243.
14. Marazziti D, Dell'Osso L, Gemignani A, Ciapparelli A, Presta S, Di Nasso E, et al. (2001). Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 16:215-219.
15. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
16. Montgomery SA, Kasper S, Stein DJ, Hedegaardd KB, Lemming OM (2001). Citalopram 20, 40 and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:75-86.
17. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE; (2004).
18. Overbeek T, Schruers K, Vermetten E, Griez E (2002). Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry 63:1106-1112.
19. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.
20. Pallanti S, Quercioli L, Koran LM (2002). Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63:796-801.
21. Rush AJ (2007). STAR*D: what have we learned? Am J Psychiatry 164: 201-204.
22. Schruers K, Koning K, Luermans J, Haack MJ, Griez E (2005). Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 111:261-271.
23. Sheehan DV (1983.) The anxiety disease. New York: Charles Scribner's Sons.
24. Stein DJ, Ipser JC, Baldwin DS, Bandelow B (2007a). Treatment of obsessive-compulsive disorder. CNS Spectr 12(2 Suppl 3):28-35.
25. Stein DJ, Andersen EW, Tonnoir B, Fineberg N (2007b). Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed dose, 24-week study. Curr Med Res Opin 23: 701-711.
26. Tollefson GD, Birkett M, Koran L, Genduso L (1994). Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 55(Suppl):69-78.
27. Vythilingum B, Cartwright C, Hollander E (2000). Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 15(Suppl 2):S7-S13.
28. Zohar J, Hollander E, Stein DJ, Westenberg HGM, The Cape Town Consensus Group (2007). Consensus statement. CNS Spectr 12(2 Suppl 3): 43-58.